There are reports about oncogenetic variants in the SLC22A4 (OCTN1) and SLC22A5 (OCTN2) genes to be linked to prolonged time to progression or optimal response to imatinib treatment in different cancers [46,100]. Here, SLC22A4 is linked to cancer.